]>
IRCT20201005048944N1 IRCT 2021-01-11 Esfahan University of Medical Sciences Evaluation of the effect of memantine for the prevention of headaches caused by head trauma Evaluation of prophylactic effect of memantine in comparison with placebo on post-traumatic headache in patients with head trauma 3 months and 6 months after starting the drug 2020-08-22 anticipated 90 Complete https://irct.ir/trial/53204 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Single, Purpose: Prevention, Randomization description: Simple randomization, table of random numbers. In this study, reading the table of predefined random numbers (eg, up or down) and the researcher's second default is to consider even numbers for intervention group . The researcher begins to read the numbers in a predetermined manner and the patients are divided, Blinding description: In order to prepare placebo and memantine (main drug), we refer to the School of Pharmacy and they provide for us two similar drug packages with the same shape without informing the researcher and the patient. After conducting the research, during the data analysis, the type of drug (placebo or memantine ) is decoded by the pharmaceutical company (Hakim). 3 post traumatic headache. Intervention 1: Intervention group: Memantine tablets are an N-methyl-D-aspartate (NMDA) receptor-dependent inhibitor of the glutamate receptor subtype.For patients in the intervention group, 10 mg of memantine tablets are prescribed for half a tablet a day for two weeks and then one tablet a day for 5 months. The manufacturer is Hakim Pharmaceutical Company. Intervention 2: Control group: A placebo is prescribed for patients in the control group. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public elham bani
School of Medicine, Isfahan University of Medical Sciences and Health Services, Hezar Jerib St
isfahan Iran (Islamic Republic of) 8174673461 +98 31 3668 0048 bani@resident.mui.ac.ir Esfahan University of Medical Sciences scientific fariborz khorvash
No. 22, Roshd Ave., Daneshgah Blvd., Isfahan
isfahan Iran (Islamic Republic of) 8174675731 +98 31 3620 2020 fkhorvash@gmail.com Esfahan University of Medical Sciences Iran (Islamic Republic of) People who have head trauma 18 years no limit Both Having a history of severe neurological disease Having a history of severe mental illness Having brain complications from trauma such as infections G44.3 post traumatic headache Prevention Placebo Intervention group: Memantine tablets are an N-methyl-D-aspartate (NMDA) receptor-dependent inhibitor of the glutamate receptor subtype.For patients in the intervention group, 10 mg of memantine tablets are prescribed for half a tablet a day for two weeks and then one tablet a day for 5 months. The manufacturer is Hakim Pharmaceutical Company. Control group: A placebo is prescribed for patients in the control group. Pain. Timepoint: 3 months and 6 months after treatment. Method of measurement: Visual Analogue Scale questionnaire. Esfahan University of Medical Sciences Approved 2020-05-08 Ethics committee of Esfahan university of Medical sciences No. 18, Hezar Jarib Ave., Daneshgah Blvd., Isfahan Isfahan Isfehan Iran (Islamic Republic of)